{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:30:17Z","timestamp":1791322217442,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014820","name":"Li Ka Shing Faculty of Medicine, University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.atherosclerosis.2021.05.016","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T12:30:36Z","timestamp":1622118636000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"special_numbering":"C","title":["Trends in lipid-modifying agent use in 83 countries"],"prefix":"10.1016","volume":"328","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-198X","authenticated-orcid":false,"given":"Joseph E.","family":"Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-6786","authenticated-orcid":false,"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.W.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5627-1633","authenticated-orcid":false,"given":"Hassan","family":"Alwafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallis C.Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"Kenneth K.C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Wah","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.B.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C.K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib2","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib3","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib4","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2013.284657","article-title":"More than a billion people taking statins?: potential implications of the new cardiovascular guidelines","volume":"311","author":"Ioannidis","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","author":"Taddei","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2020.12.025","article-title":"Trends in cardiovascular medicine use in 65 middle- and high-income countries","volume":"77","author":"Yan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib8","author":"Quintiles IMS"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib9","author":"IQVIA"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(18)30547-4","article-title":"Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries","volume":"19","author":"Hsia","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib11","author":"United Nations"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib12","author":"World Bank"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib13","author":"WHO"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib14","series-title":"The SAGE Dictionary of Quantitative Management Research","article-title":"Growth models","author":"Sokele","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib15","author":"European Medicines Agency"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMsa0801461","article-title":"Use of ezetimibe in the United States and Canada","volume":"358","author":"Jackevicius","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jama.2011.353","article-title":"Use of fibrates in the United States and Canada","volume":"305","author":"Jackevicius","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamainternmed.2013.6489","article-title":"Use of niacin in the United States and Canada","volume":"173","author":"Jackevicius","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","article-title":"Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997\u20132003","volume":"60","author":"Walley","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2125.2004.02256.x","article-title":"The influence of guidelines on the use of statins: analysis of prescribing trends 1998\u20132002","volume":"59","author":"Teeling","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010500","article-title":"Time trends in statin utilisation and coronary mortality in Western European countries","volume":"6","author":"Vancheri","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003811","article-title":"Twenty-year nationwide trends in statin utilization and expenditure in Denmark","volume":"10","author":"Mortensen","year":"2017","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/pds.2045","article-title":"Consumption of serum lipid-reducing drugs in Serbia compared with Scandinavian countries: a population-based study, 2004\u20132008","volume":"20","author":"Sabo","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2471\/BLT.10.079947","article-title":"High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries","volume":"89","author":"Roth","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1377\/hlthaff.2013.0388","article-title":"Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries","volume":"33","author":"Choudhry","year":"2014","journal-title":"Health Aff."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2018.11.015","article-title":"Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004\u20132015","volume":"280","author":"Blais","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014150","article-title":"10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database","volume":"7","author":"Hsieh","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065228","article-title":"Trends in total and low-density lipoprotein cholesterol among U.S. adults: Contributions of changes in dietary fat intake and use of cholesterol-lowering medications","volume":"8","author":"Ford","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123112","article-title":"Quantifying the contribution of statins to the decline in population mean cholesterol by socioeconomic group in England 1991 - 2012: a modelling study","volume":"10","author":"Kypridemos","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ije\/dyz099","article-title":"National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries","volume":"49","author":"NCD Risk Factor Collaboration","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1017\/S1368980010001126","article-title":"Explaining the 25-year decline of serum cholesterol by dietary changes and use of lipid-lowering medication in Finland","volume":"13","author":"Valsta","year":"2010","journal-title":"Public Health Nutr."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/1753-6405.12504","article-title":"Trends in serum total cholesterol and dietary fat intakes in New Zealand between 1989 and 2009","volume":"40","author":"Miller","year":"2016","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib35","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib37","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib39","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib40","first-page":"92","article-title":"Trends in utilization and cost of low-density lipoprotein cholesterol-lowering therapies among Medicare beneficiaries: an analysis from the Medicare Part D database","volume":"6","author":"Sumarsono","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib41","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib43","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.016_bib44","author":"Pagliarulo"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:46:06Z","timestamp":1758156366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":43,"alternative-id":["S0021915021002525"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.10.21249523","asserted-by":"object"}]},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in lipid-modifying agent use in 83 countries","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}